142 related articles for article (PubMed ID: 2066980)
1. Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan.
Flouret G; Brieher W; Majewski T; Mahan K; Wilson L
J Med Chem; 1991 Jul; 34(7):2089-94. PubMed ID: 2066980
[TBL] [Abstract][Full Text] [Related]
2. Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan.
Flouret G; Brieher W; Majewski T; Mahan K; Wilson L
Int J Pept Protein Res; 1991 Aug; 38(2):169-75. PubMed ID: 1783491
[TBL] [Abstract][Full Text] [Related]
3. Design of potent oxytocin antagonists featuring D-tryptophan at position 2.
Flouret G; Brieher W; Mahan K; Wilson L
J Med Chem; 1991 Feb; 34(2):642-6. PubMed ID: 1995888
[TBL] [Abstract][Full Text] [Related]
4. Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue.
Flouret G; Majewski T; Brieher W; Wilson L
J Med Chem; 1993 Mar; 36(6):747-9. PubMed ID: 8459401
[TBL] [Abstract][Full Text] [Related]
5. Antagonists of oxytocin featuring replacement with modified beta-mercaptopropionic acids at position 1.
Flouret G; Majewski T; Balaspiri L; Brieher W; Mahan K; Chaloin O; Wilson L; Slaninová J
J Pept Sci; 2002 Jul; 8(7):314-26. PubMed ID: 12148781
[TBL] [Abstract][Full Text] [Related]
6. Analogues of a potent oxytocin antagonist with truncated C-terminus or shorter amino acid side chain of the basic amino acid at position 8.
Flouret G; Chaloin O; Slaninová J
J Pept Sci; 2003 Jun; 9(6):393-401. PubMed ID: 12846485
[TBL] [Abstract][Full Text] [Related]
7. Design of novel bicyclic analogues derived from a potent oxytocin antagonist.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 Jun; 12(6):412-9. PubMed ID: 16432806
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.
Manning M; Miteva K; Pancheva S; Stoev S; Wo NC; Chan WY
Int J Pept Protein Res; 1995; 46(3-4):244-52. PubMed ID: 8537178
[TBL] [Abstract][Full Text] [Related]
9. Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.
Manning M; Cheng LL; Klis WA; Balaspiri L; Olma A; Sawyer WH; Wo NC; Chan WY
J Med Chem; 1995 May; 38(10):1762-9. PubMed ID: 7752199
[TBL] [Abstract][Full Text] [Related]
10. Design of oxytocin antagonists, which are more selective than atosiban.
Manning M; Stoev S; Cheng LL; Wo NC; Chan WY
J Pept Sci; 2001 Sep; 7(9):449-65. PubMed ID: 11587184
[TBL] [Abstract][Full Text] [Related]
11. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists.
Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469
[TBL] [Abstract][Full Text] [Related]
12. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
13. Analogues of oxytocin antagonists bearing a ureido group in the amino acid side chain at position 4 or 5.
Flouret G; Chaloin O; Borovickova L; Slaninová J
J Pept Sci; 2006 May; 12(5):347-53. PubMed ID: 16285023
[TBL] [Abstract][Full Text] [Related]
14. Decreased histamine release by luteinizing hormone-releasing hormone antagonists obtained upon translocation of the cationic amino acid from position 8 to position 7.
Flouret G; Mahan K; Majewski T
J Med Chem; 1992 Feb; 35(4):636-40. PubMed ID: 1371810
[TBL] [Abstract][Full Text] [Related]
15. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
16. Potent antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta,beta-cyclopentamethylenepropionic acid),2-D- phenylalanine,4-valine]arginine-vasopressin at position 4.
Manning M; Olma A; Klis WA; Seto J; Sawyer WH
J Med Chem; 1983 Nov; 26(11):1607-13. PubMed ID: 6631916
[TBL] [Abstract][Full Text] [Related]
17. Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.
Pavo I; Slaninova J; Klein U; Fahrenholz F
J Med Chem; 1994 Jan; 37(2):255-9. PubMed ID: 7507528
[TBL] [Abstract][Full Text] [Related]
18. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
[TBL] [Abstract][Full Text] [Related]
19. Design of potent and selective linear antagonists of vasopressor (V1-receptor) responses to vasopressin.
Manning M; Stoev S; Kolodziejczyk A; Klis WA; Kruszynski M; Misicka A; Olma A; Wo NC; Sawyer WH
J Med Chem; 1990 Nov; 33(11):3079-86. PubMed ID: 2231609
[TBL] [Abstract][Full Text] [Related]
20. 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.
Williams PD; Anderson PS; Ball RG; Bock MG; Carroll L; Chiu SH; Clineschmidt BV; Culberson JC; Erb JM; Evans BE
J Med Chem; 1994 Mar; 37(5):565-71. PubMed ID: 8126695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
